翻訳と辞書
Words near each other
・ Michael Jay Moon
・ Michael Jay, Baron Jay of Ewelme
・ Michael Jayasekera
・ Michael Jayston
・ Michael Jecks
・ Michael Jefferson
・ Michael Jefferson Nascimento
・ Michael Jeffery
・ Michael Jeffery (disambiguation)
・ Michael Jeffery (manager)
・ Michael Jeffrey
・ Michael Jeffrey Shapiro
・ Michael Jeffries
・ Michael Jeffries (singer)
・ Michael Jeh
Michael Jeltsch
・ Michael Jemtrud
・ Michael Jenkins
・ Michael Jenkins (basketball)
・ Michael Jenkins (diplomat)
・ Michael Jenkins (running back)
・ Michael Jenkins (sportscaster)
・ Michael Jenkins (wide receiver)
・ Michael Jenkins Moynihan
・ Michael Jennings
・ Michael Jennings (American football)
・ Michael Jennings (boxer)
・ Michael Jennings (rugby league)
・ Michael Jensen
・ Michael Jepsen Jensen


Dictionary Lists
翻訳と辞書 辞書検索 [ 開発暫定版 ]
スポンサード リンク

Michael Jeltsch : ウィキペディア英語版
Michael Jeltsch

Michael Jeltsch (born July 28, 1969, Hemer/NW, Germany) is a German researcher in the field of Biochemistry. He is an adjunct professor in University of Helsinki, Finland. He has more than 50 publications.〔(【引用サイトリンク】url=http://www.researcherid.com/rid/I-5340-2012 )〕 Jeltsch was the first to show that VEGF-C and VEGF-D are the principal growth factors for the lymphatic vasculature and his research focuses on cancer drug targets and lymphangiogenesis. He has also contributed to other seminal publications in cell biology with transgenesis, protein engineering, recombinant production and purification. In 2006, he developed a synthetic super-VEGF, using a library of VEGF hybrid molecules using a novel, non-random DNA family shuffling method.
Jeltsch completed his graduation, postgraduation, and postdoc at Molecular/Cancer Biology Lab, University of Helsinki, Helsinki, Finland. He worked as a researcher at Lymphatix Ltd. (now Ark Therapeutics) via Licentia Ltd., Helsinki, Finland (April 2006 – January 2007) and at Circadian Technologies via Vegenics Ltd. via Licentia Ltd., Helsinki, Finland (February 2007 – December 2011), where he was involved in the development of VEGF-C and VEGF-D as drugs and anticancer drugs. He was a Postdoctoral Fellow at Wihuri Research Institute, Helsinki, Finland from January 2013 to August 2013. Since 2013, he is a Group leader and Academy Research Fellow at Helsingin yliopisto - University of Helsinki, Helsinki, Finland. Jeltsch lab is affiliated with Translational Cancer Biology Research Program and Institute of Biomedicine.
In June 1994, he received a one-year scholarship by the German Academic Exchange Service (DAAD). He was awarded Medix Prize by the Minerva Foundation Institute for Medical Research for best biomedical publication of the year in Finland in March 1997. In December 2002, he received Talentum Award by the KAUTE Foundation for best PhD thesis in the field of biotechnology in Finland. In 2015, he received the “Best Paper Award” in the category of Basic Science by ''Circulation'', the journal of the American Heart Association for his 2014 work, in which
he identified the molecular mechanism behind Hennekam syndrome.
==References==



抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)
ウィキペディアで「Michael Jeltsch」の詳細全文を読む



スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース

Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.